  | Sharma, M., Beaudart, C., Clark, P., Fujiwara, S., Adachi, J. D., Papaioannou, A., Messina, O. D., Morin, S. N., Kohlmeier, L., Nogues, X., Leckie, C., Harvey, N. C., Kanis, J. A., Reginster, J.-Y., Hiligsmann, M., & Silverman, S. L. (2024). Clinical and demographic factors determining patient fracture risk decision point (FRDP): The improving risk communication in osteoporosis (RICO) project. Osteoporosis International. doi:10.1007/s00198-024-07264-5  Peer Reviewed verified by ORBi |
 | Kanis, J. A., Harvey, N. C., Lorentzon, M., Liu, E., Schini, M., Abrahamsen, B., Adachi, J. D., Alokail, M., Borgstrom, F., Bruyère, O., Carey, J. J., Clark, P., Cooper, C., Curtis, E. M., Dennison, E. M., Díaz-Curiel, M., Dimai, H. P., Grigorie, D., Hiligsmann, M., ... Board of IOF, A. T. I. W. G. O. E. A. Q. O. L. (September 2024). Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk. Osteoporosis International, 35 (9), 1487 - 1496. doi:10.1007/s00198-024-07162-w Peer Reviewed verified by ORBi |
 | Li, N., Jørgensen, N. R., Reginster, J.-Y., & Hiligsmann, M. (September 2024). The impact of bone turnover marker on medication adherence and the health economics-related consequences. Expert Review of Pharmacoeconomics and Outcomes Research, 24 (7), 787 - 790. doi:10.1080/14737167.2024.2337718 Peer Reviewed verified by ORBi |
 | Veronese, N., Briot, K., Guañabens, N., Albergaria, B. H., Alokail, M., Al-Daghri, N., Bemden, A. B.-V., Bruyère, O., Burlet, N., Cooper, C., Curtis, E. M., Ebeling, P. R., Halbout, P., Hesse, E., Hiligsmann, M., Camargos, B. M., Harvey, N. C., Perez, A. D., Radermecker, R., ... Brandi, M. L. (09 August 2024). Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clinical and Experimental Research, 36 (1), 167. doi:10.1007/s40520-024-02826-3 Peer Reviewed verified by ORBi |
 | Fuggle, N. R., Beaudart, C., Bruyère, O., Abrahamsen, B., Al-Daghri, N., Burlet, N., Chandran, M., Rosa, M. M., Cortet, B., Demonceau, C., Dere, W., Halbout, P., Hiligsmann, M., Kanis, J. A., Kaufman, J.-M., Kurth, A., Lamy, O., Laslop, A., Maggi, S., ... Harvey, N. C. (14 March 2024). Evidence-Based Guideline for the management of osteoporosis in men. Nature Reviews Rheumatology, 20 (4), 241-251. doi:10.1038/s41584-024-01094-9 Peer Reviewed verified by ORBi |
 | Beaudart, C., Sharma, M., Clark, P., Fujiwara, S., Adachi, J. D., Messina, O. D., Morin, S. N., Kohlmeier, L. A., Sangan, C. B., Nogues, X., Cruz-Priego, G. A., Cavallo, A., Cooper, F., Grier, J., Leckie, C., Montiel-Ojeda, D., Papaioannou, A., Raskin, N., Yurquina, L., ... Hiligsmann, M. (March 2024). Patients' preferences for fracture risk communication: the Risk Communication in Osteoporosis (RICO) study. Osteoporosis International, 35 (3), 451-468. doi:10.1007/s00198-023-06955-9 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Silverman, S. L., Singer, A. J., Pearman, L., Wang, Y., Caminis, J., & Reginster, J.-Y. (30 January 2024). Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures. Aging Clinical and Experimental Research, 36 (1), 14. doi:10.1007/s40520-023-02682-7 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Bruyère, O. (2024). The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example. Global and Regional Health Technology Assessment, 11 (1), 75 - 81. doi:10.33393/grhta.2024.2682 Peer Reviewed verified by ORBi |
 | Beaudart, C., Tilquin, N., Abramowicz, P., Baptista, F., Peng, D. J., de Souza Orlandi, F., Drey, M., Dzhus, M., Fábrega-Cuadros, R., Fernandez-Garrido, J., Laurindo, L. F., Gasparik, A.-I., Geerinck, A., Emin, G., Iacob, S., Kilaitė, J., Kumar, P., Lee, S.-C., Lou, V. W. Q., ... Bruyère, O. (15 December 2023). Quality of life in sarcopenia measured with the SarQoL questionnaire: A meta-analysis of individual patient data. Maturitas, 180, 107902. doi:10.1016/j.maturitas.2023.107902 Peer Reviewed verified by ORBi |
 | Moon, R. J., Reginster, J.-Y., Al-Daghri, N., Thiyagarajan, J. A., Beaudart, C., Bruyère, O., Burlet, N., Chandran, M., da Silva, M. C., Conaghan, P. G., Dere, W. H., Diez-Perez, A., Hadji, P., Halbout, P., Hiligsmann, M., Kanis, J. A., McCloskey, E. V., Ormarsdottir, S., Prieto-Alhambra, D., ... Harvey, N. C. (August 2023). Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporosis International, 34 (8), 1283 - 1299. doi:10.1007/s00198-023-06827-2 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Silverman, S. S., Singer, A. J., Pearman, L., Mathew, J., Wang, Y., Caminis, J., & Reginster, J.-Y. (2023). Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States. PharmacoEconomics. doi:10.1007/s40273-023-01270-x Peer Reviewed verified by ORBi |
 | Li, N., Beaudart, C., Cauley, J. A., Ing, S. W., Lane, N. E., Reginster, J.-Y., Silverman, S., Singer, A. J., & Hiligsmann, M. (April 2023). Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics, 41 (4), 363 - 391. doi:10.1007/s40273-022-01239-2 Peer Reviewed verified by ORBi |
 | Li, N., Beaudart, C., Cauley, J. A., Ing, S. W., Lane, N. E., Reginster, J.-Y., Silverman, S., Singer, A. J., & Hiligsmann, M. (April 2023). Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics, 41 (4), 393. doi:10.1007/s40273-023-01255-w Peer Reviewed verified by ORBi |
 | Fuggle, N., Al-Daghri, N., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M., Giusti, A., Halbout, P., Harvey, N. C., Hiligsmann, M., Kaufman, J.-M., Kurth, A., Maggi, S., Matijevic, R., Minisola, S., Palacios, S., ... Cooper, C. (03 January 2023). Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clinical and Experimental Research, online. doi:10.1007/s40520-022-02319-1 Peer Reviewed verified by ORBi |
 | Fuggle, N., Bere, N., Bruyère, O., Rosa, M. M., Prieto Yerro, M. C., Dennison, E., Dincer, F., Gabay, C., Haugen, I. K., Herrero-Beaumont, G., Hiligsmann, M., Hochberg, M. C., Laslop, A., Matijevic, R., Maheu, E., Migliore, A., Pelletier, J.-P., Radermecker, R., Rannou, F., ... Reginster, J.-Y. (2022). Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach. Aging Clinical and Experimental Research. doi:10.1007/s40520-022-02176-y Peer Reviewed verified by ORBi |
 | Chotiyarnwong, P., McCloskey, E. V., Harvey, N., Lorentzon, M., Prieto-Alhambra, D., Abrahamsen, B., Adachi, J. D., Borgström, F., Bruyère, O., Carey, J. J., Clark, P., Cooper, C., Curtis, E. M., Dennison, E., Diaz-Curiel, M., Dimai, H. P., Grigorie, D., Hiligsmann, M., Khashayar, P., ... Kanis, J. A. (2022). Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Archives of Osteoporosis, 17 (1), 87. doi:10.1007/s11657-022-01117-6 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Silverman, S., Singer, A., Pearman, L., Mathew, J., Wang, Y., Caminis, J., & Reginster, J.-Y. (2022). Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate in US men at imminent risk of fracture. Journal of Managed Care and Specialty Pharmacy, 28, 105. Peer Reviewed verified by ORBi |
 | Dangouloff, T., Servais, L., & Hiligsmann, M. (2020). SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES: P.187 Systematic literature review of the economic burden and economic evaluations in spinal muscular atrophy. Neuromuscular Disorders. doi:10.1016/j.nmd.2020.08.189 Peer Reviewed verified by ORBi |
 | Dangouloff, T., Servais, L., & Hiligsmann, M. (2020). SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES: P.191 Preliminary data for the cost-effectiveness assessment of the newborn screening for SMA in Belgium. Neuromuscular Disorders. doi:10.1016/j.nmd.2020.08.193 Peer Reviewed verified by ORBi |
 | Leclercq, V., Hiligsmann, M., Parisi, G., Beaudart, C., Tirelli, E., & Bruyère, O. (February 2020). Prioritization of items of the AMSTAR 2 tool to critically appraise systematic reviews and meta-analyses: A best-worst scaling approach [Paper presentation]. REWARD EQUATOR Conference 2020. |
 | Dangouloff, T., Burghes, A., Bertini, E., BOEMER, F., Hiligsmann, M., Mueller-Felber, W., Tiziano, F. D., Young, P., Germanenko, O., De Lemus, M., Ouillade, L., Rucinski, K., Stephenson, K., Farwell, W., Gorni, K., Hjort, M., Kausar, I., Tizzano, E. F., & Servais, L. (January 2020). 244th ENMC International Workshop: Newborn screening in Spinal Muscular Atrophy May 10-12, 2019, Hoofdorp, The Netherlands. Neuromuscular Disorders, 30 (1), 93-103. doi:10.1016/j.nmd.2019.11.002 Peer Reviewed verified by ORBi |
  | Leclercq, V., Hiligsmann, M., Parisi, G., Beaudart, C., Tirelli, E., & Bruyère, O. (2020). Best-worst scaling identified adequate statistical methods and literature search as the most important items of AMSTAR2 (A measurement tool to assess systematic reviews). Journal of Clinical Epidemiology, 128, 74-82. doi:10.1016/j.jclinepi.2020.08.011 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Reginster, J.-Y., Tosteson, A. N. A., Bukata, S. V., Saag, K. G., Gold, D. T., Halbout, P., Jiwa, F., Lewiecki, E. M., Pinto, D., Adachi, J. D., Al-Daghri, N., Bruyère, O., Chandran, M., Cooper, C., Harvey, N. C., Einhorn, T. A., Kanis, J. A., Kendler, D. L., ... Silverman, S. (January 2019). Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International, 30 (1), 45-57. doi:10.1007/s00198-018-4744-x Peer Reviewed verified by ORBi |
 | Dangouloff, T., Hiligsmann, M., CABERG, J.-H., BOEMER, F., & Servais, L. (2018). Development of a decision-analytic model for the economic evaluation of newborn screening for spinal muscular atrophy. Neuromuscular Disorders, 28 (S29–S146), 59. doi:10.1016/j.nmd.2018.06.125 Peer Reviewed verified by ORBi |
 | Ethgen, O., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2015). Cost-effectiveness of dairy products supplemented with vitamin D in the prevention of osteoporotic fractures. Osteoporosis International, 26 (S1), 372-S373. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Evers, S. M., Ben Sedrine, W., Kanis, J. A., Ramaekers, B., Reginster, J.-Y., Silverman, S., Wyers, C. E., & Boonen, A. (2015). A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. PharmacoEconomics, 33 (3), 205-224. doi:10.1007/s40273-014-0231-1 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., Evers, S. M., Rabenda, V., & Reginster, J.-Y. (2015). Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. European Journal of Public Health, 25 (1), 20-25. doi:10.1093/eurpub/cku119 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., Jeholet, P., Misson, V., Pire, G., & Reginster, J.-Y. (2014). Economic evaluation of an osteoporosis screening campaign: using FRAX as a prescreening tool. Osteoporosis International, 25 (2), 38-39. Peer Reviewed verified by ORBi |
 | Rizzoli, R., Branco, J., Brandi, M., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C., Diez-Perez, A., Duder, J., Fielding, R., Harvey, N., Hiligsmann, M., Kanis, J., Petermans, J., Ringe, J., Tsouderos, Y., Weinman, J., & Reginster, J.-Y. (2014). Erratum to: Management of osteoporosis of the oldest old. Osteoporosis International, 25, 2531. doi:10.1007/s00198-014-2830-2 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Dellaert, B., Dirksen, C., Van der Weijden, T., Watson, V., Goemaere, S., Reginster, J.-Y., Roux, C., Mcgowan, B., Silke, C., Whelan, B., Diez-Perez, A., Torres, E., Papadakis, G., Rizzoli, R., Cooper, C., Pearson, G., & Boonen, A. (2014). Preferences of patients for osteoporosis drug treatment: a cross-european discrete choice experiment. Osteoporosis International, 25 (2), 227-228. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Dellaert, B. G., Dirksen, C. D., van der Weijden, T., Goemaere, S., Reginster, J.-Y., Watson, V., & Boonen, A. (2014). Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Research and Therapy, 16 (1), 36. doi:10.1186/ar4465 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Cooper, C., Guillemin, F., Hochberg, M. C., Tugwell, P., Arden, N., Berenbaum, F., Boers, M., Boonen, A., Branco, J. C., Maria-Luisa, B., Bruyère, O., Gasparik, A., Kanis, J. A., Kvien, T. K., Martel-Pelletier, J., Pelletier, J.-P., Pinedo-Villanueva, R., Pinto, D., ... Reginster, J.-Y. (2014). A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 44, 271-282. doi:10.1016/j.semarthrit.2014.06.005 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Branco, J., Brandi, M.-L., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C., Diez-Perez, A., Duder, J., Fielding, R. A., Harvey, N. C., Hiligsmann, M., Kanis, J. A., Petermans, J., Ringe, J. D., Tsouderos, Y., Weinman, J., & Reginster, J.-Y. (2014). Management of osteoporosis of the oldest old. Osteoporosis International, 25, 2507-2529. doi:10.1007/s00198-014-2755-9 Peer Reviewed verified by ORBi |
 | Bruyère, O., Hiligsmann, M., Zegels, B., NEUPREZ, A., & Reginster, J.-Y. (September 2013). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: A 3-year study. International Journal of Gerontology, 7 (3), 167-70. doi:10.1016/j.ijge.2012.11.015 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Cooper, C., Arden, N., Boers, M., Branco, J., Brandi, M. L., Bruyère, O., Guillemin, F., Hochberg, M., Hunter, D., Kanis, J. A., Kvien, T., Laslop, A., Petit-Dop, F., Pelletier, J.-P., Pinto, D., Reiter, S., Rizzoli, R., Rovati, L. C., ... Reginster, J.-Y. (April 2013). Health economics in osteoarthritis. Osteoporosis International, 24 (Suppl.1), 79-80. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (April 2013). Cost-effectiveness of vitamin D and calcium supplementation in the treatment of postmenopausal women. Osteoporosis International, 24 (Suppl.1), 198. Peer Reviewed verified by ORBi |
 | Bruyère, O., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., Neuprez, A., & Reginster, J.-Y. (April 2013). Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatology International, 33 (4), 973-8. doi:10.1007/s00296-012-2460-y Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Kanis, J. A., Compston, J., Cooper, C., Flamion, B., Bergmann, P., Body, J.-J., Boonen, S., Bruyère, O., Devogelaer, J.-P., Goemaere, S., Kaufman, J.-M., Rozenberg, S., & Reginster, J.-Y. (March 2013). Health Technology Assessment in Osteoporosis. Calcified Tissue International, 93 (1), 1-14. doi:10.1007/s00223-013-9724-8 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., & Reginster, J.-Y. (February 2013). Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporosis International, 24 (8), 2291-300. doi:10.1007/s00198-013-2272-2 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., VAN DURME, C., Geusens, P., Dellaert, B. G., Dirksen, C. D., van der Weijden, T., Reginster, J.-Y., & Boonen, A. (2013). Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Preference and Adherence, 7, 133-9. doi:10.2147/PPA.S38408 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2013). Health Economics Analyses in Osteoporosis. In R. Arinoviche Schenker & M. Arriagada Maldini (Eds.), Temas de osteoporosis y otras enfermedades oseas (pp. 337-358). Santiago, Chile: Fundacion Chilena de osteoporosis. Peer reviewed |
 | Hiligsmann, M., Dellaert, B., Dirksen, C., Van der Weijden, T., Goemaere, S., Reginster, J.-Y., Watson, V., & Boonen, A. (2013). Patients' preferences for osteoporosis drug therapy : a discrete choice experiment. Osteoporosis International, 24 (1), 53. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Boonen, A., Dirksen, C. D., Ben Sedrine, W., & REGINSTER, J.-Y. (2013). Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. Expert Review of Pharmacoeconomics and Outcomes Research, 13 (1), 19-28. doi:10.1586/erp.12.76 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., & REGINSTER, J.-Y. (2013). Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. Journal of Bone and Mineral Research, 28 (4), 807-15. doi:10.1002/jbmr.1819 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Cooper, C., Arden, N., Boers, M., Branco, J. C., Luisa Brandi, M., Bruyère, O., Guillemin, F., Hochberg, M. C., Hunter, D. J., Kanis, J. A., Kvien, T. K., Laslop, A., Pelletier, J.-P., Pinto, D., Reiter-Niesert, S., Rizzoli, R., Rovati, L. C., Severens, J. L. H., ... REGINSTER, J.-Y. (2013). Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 43 (3), 303-313. doi:10.1016/j.semarthrit.2013.07.003 Peer Reviewed verified by ORBi |
 | Svedbom, A., Hernlund, E., Ivergard, M., Compston, J., Cooper, C., Stenmark, J., McCloskey, E., Jonsson, B., Kanis, J., Hiligsmann, M., & Reginster, J.-Y. (2013). Osteoporosis in the European Union : a compendium of country-specific reports. Archives of Osteoporosis, 8 (137), 1-218. doi:10.1007/s11657-013-0137-0 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Roberfroid, D., Dubois, C., Parmentier, Y., Carton, J., Detilleux, J., GILLET, P., & Reginster, J.-Y. (May 2012). Trends in hip fracture incidence and in the prescription of anti-osteoporosis medications during same time period in Belgium (2000-2007). Arthritis Care and Research, 64 (5), 744-750. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Van Durme, C., Geusens, P., Dellaert, B., Dirksen, C., Van der Weijden, T., Reginster, J.-Y., & Boonen, A. (March 2012). What are the most important medication attributes for patients with osteoporosis ? Results from a qualitative study. Osteoporosis International, 23 (S2), 81-82. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., & Reginster, J.-Y. (March 2012). Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 23 (Suppl. 2), 312-313. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., & Reginster, J.-Y. (March 2012). An economic evaluation of strontium ranelate for the treatment of male osteoporosis. Osteoporosis International, 23 (Suppl. 2), 305-306. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Boonen, A., Rabenda, V., & REGINSTER, J.-Y. (2012). The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 12 (2), 159-66. doi:10.1586/erp.12.8 Peer Reviewed verified by ORBi |
| Hiligsmann, M., Van Durme, C., Geusens, P., Dellaert, B., Dirksen, C., Van der Weijden, T., Reginster, J.-Y., & Boonen, A. (2012). Nominal group technique to prioritize preferences for medication attributes from the patients’ perspective : the case of osteoporosis. Annals of the Rheumatic Diseases, 71 (3), 597. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2012). Incidence des fractures de hanche en fonction des médicaments prescrits contre l'ostéoporose. Ortho-Rhumato, 10 (4), 3. Peer reviewed |
 | Hiligsmann, M., Ben Sedrine, W., & Reginster, J.-Y. (2012). Cost-effectiveness of Bazedoxifene compared with Raloxifene in the treatment of postmenopausal osteoporotic women. Arthritis and Rheumatism, 64 (S10), 834. Peer Reviewed verified by ORBi |
 | Kanis, J. A., Reginster, J.-Y., Kaufman, J. M., Ringe, J. D., Adachi, J. D., Hiligsmann, M., Rizzoli, R., & Cooper, C. (2012). A reappraisal of generic bisphosphonates in osteoporosis. Osteoporosis International, 23, 213-221. doi:10.1007/s00198-011-1796-6 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., McGowan, B., Bennett, K., Barry, M., & REGINSTER, J.-Y. (2012). The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value in Health, 15 (5), 604-12. doi:10.1016/j.jval.2012.02.001 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Hiligsmann, M. (2012). Economics in osteoporosis : how can we reconciliate the prescribers and the payer ? Osteoporosis International, 23 (6), 655-S661. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2012). Un monde médical et économique en pleine évolution : maladies complexes et intérêt de l’évaluation économique des technologies de santé. Revue Médicale de Liège, 67 (5-6), 258-262. Peer reviewed |
 | Hiligsmann, M., Van Durme, C., Geusens, P., Dellaert, B., Dirksen, C., Van Der Weijden, T., Reginster, J.-Y., & Boonen, A. (2012). Quelles sont les caractéristiques des médicaments les plus importantes pour les patients ostéoporotiques ? Résultats d'une étude qualitative. Revue du Rhumatisme, 79 (S1), 238. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Roberfroid, D., Dubois, C., Parmentier, Y., Carton, J., Detilleux, J., Gillet, P., & Reginster, J.-Y. (December 2011). Evolution récente de l'incidence des fractures de hanche et de la consommation de médicaments anti-ostéoporotiques en Belgique. Revue du Rhumatisme, 78 (Suppl. 5), 43-44. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., McGowan, B., Bennett, K., Barry, M., & Reginster, J.-Y. (November 2011). The clinical and economic implications of non-adherence with osteoporosis medications in Ireland [Paper presentation]. ESPACOMP Meeting, Utrecht, Netherlands. |
Hiligsmann, M. (2011). Interest of Health Economic Analyses [Paper presentation]. Yearly debates on Orthopeadics, La Hulpe, Belgium. |
Hiligsmann, M., & Reginster, J.-Y. (04 October 2011). Actualités dans le diagnostic et le traitement de l'ostéoporose: aspects cliniques et pharmaco-économiques [Paper presentation]. Enseignement Post Universitaire, Liège, Belgium. |
Hiligsmann, M. (August 2011). The importance of integrating medication adherence in pharmacoeconomic analyses: the example of osteoporosis [Paper presentation]. MTA (Medical Technology Assessment) seminar, Maastricht, Netherlands. |
 | Hiligsmann, M., Bruyère, O., Pire, G., & Reginster, J.-Y. (June 2011). Economic evaluation of osteoporosis screening strategy conducted in the Province of Liège with the cooperation of Liège Province Santé [Paper presentation]. WHO European Healthy Cities Networks Phase V (2009-2013). Third Annual Business & Technical Conference, Liège, Belgium. |
 | Hiligsmann, M., & Rabenda, V. (24 March 2011). Basing adherence on empirical observations and how does partial adherence impact on anti-fracture efficacy [Paper presentation]. ECCEO-IOF 11 European Congress on Osteoporosis & Osteoarthritis, Valencia, Spain. |
 | Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (March 2011). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: a 3-year study. Osteoporosis International, 22 (Suppl.1), 332-333. Peer Reviewed verified by ORBi |
 | Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (March 2011). Compliance to daily placebo treatment in a postmenopausal osteoporotic women population: characteristics and impact on mortality. Osteoporosis International, 22 (Suppl.1), 287-288. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (March 2011). Cost-effectiveness of Denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 22 (Suppl.1), 112-113. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Gathon, H.-J., Bruyère, O., Daubie, M., Parmentier, Y., Dercq, J.-P., & Reginster, J.-Y. (March 2011). Hospitalisation costs of hip fractures in Belgium. Osteoporosis International, 22 (Suppl.1), 332. Peer Reviewed verified by ORBi |
 | Bruyère, O., Neuprez, A., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., & Reginster, J.-Y. (March 2011). Reimbursement of drugs against osteoporosis based on FRAX® instead of the current criteria would reduce by 30% the cost (in a societal perspective) of anti-osteoporosis treatment in Belgium. Osteoporosis International, 22 (Suppl.1), 333-334. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Gathon, H.-J., Bruyère, O., Beaudart, C., Kolh, P., JACQUES, J., Gillet, P., & Reginster, J.-Y. (March 2011). Patient out-of-pocket contributions related to hip fracture hospital costs in Belgium. Osteoporosis International, 22 (Suppl.1), 333. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Salas, M., Hughes, D. A., Manias, E., Gwadry-Sridhar, F., Linck, P., & Cowell, W. (March 2011). Most Effective Interventions to Improve Patient Compliance with Osteoporosis Medications. Osteoporosis International, 22 (Suppl 1), 335. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Detilleux, J., Gillet, P., Parmentier, Y., Dercq, J.-P., Carton, J., & Reginster, J.-Y. (March 2011). Incidence of hip fracture in Belgium between 2000 and 2007 and future projections. Osteoporosis International, 22 (Suppl.1), 145. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., McGowan, B., Bennett, K., Barry, M., & Reginster, J.-Y. (2011). The clinical and economic burden of poor adherence with osteoporosis medications in Ireland. Value in Health, 14, 312. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2011). Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. PharmacoEconomics, 29 (10), 895-911. doi:10.2165/11539980-000000000-00000 Peer Reviewed verified by ORBi |
 | Johansson, H., Kanis, J. A., McCloskey, E. V., Oden, A., Devogelaer, J. P., Kaufman, J. M., Neuprez, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2011). A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporosis International, 22 (2), 453-61. doi:10.1007/s00198-010-1218-1 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Cooper, C., Hiligsmann, M., Rabenda, V., Reginster, J.-Y., & Rizzoli, R. (2011). Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporosis International, 22 (10), 2565-73. doi:10.1007/s00198-011-1668-0 Peer Reviewed verified by ORBi |
 | Bruyère, O., Neuprez, A., Fossi, M., Beaudart, C., Zegels, B., Leonori, L., Hiligsmann, M., & Reginster, J.-Y. (November 2010). Le remboursement des traitements contre l'ostéoporose basé sur l'utilisation de l'outil FRAX plutôt que sur les critères actuels permettrait de réduire de 30% le coût, dans une perspective sociétale, du traitement de l'ostéoporose en Belgique. Revue du Rhumatisme, 77 (Suppl.3), 66-67. Peer Reviewed verified by ORBi |
 | Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (November 2010). Résider en institution : un facteur de risque indépendant de fractures de hanche ? Une étude prospective d’une durée de 3 ans. Revue du Rhumatisme, 77 (Suppl.3), 67-68. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (November 2010). Cost-effectiveness of denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women. Value in Health, 13 (7), 309. doi:10.1016/S1098-3015(11)72193-3 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Detilleux, J., Gillet, P., Parmentier, Y., Dercq, J.-P., Carton, J., & Reginster, J.-Y. (November 2010). Trend of hip fracture incidence in Belgium between 2000 and 2007 and future projections. Value in Health, 13 (7), 303. doi:10.1016/S1098-3015(11)72162-3 Peer Reviewed verified by ORBi |
Hiligsmann, M., & Reginster, J.-Y. (November 2010). Intérêts des analyses économiques dans la prise en charge de l’ostéoporose postménopausée. |
 | Hiligsmann, M. (November 2010). Analyse coût-efficacité des traitements anti-osteoporotiques [Paper presentation]. Colloques cliniques du service des maladies osseuses, Genève, Switzerland. |
 | Reginster, J.-Y., Hiligsmann, M., & Bruyère, O. (June 2010). Strontium ranelate: long-term efficacy against vertebral, nonvertebral and hip fractures in patients with postmenopausal osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 2 (3), 133-143. doi:10.1177/1759720X10362824 Peer Reviewed verified by ORBi |
 | SCHOLTISSEN, S., Bruyère, O., Neuprez, A., Severens, H., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (May 2010). Cost-effectiveness of glucosamine sulfate compared to acetaminophen in the treatment of knee osteoarthrits: a French health care perspective. Osteoporosis International, 21 (Suppl.1), 167. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (May 2010). Cost-effectiveness of denosumab compared with oral bisphosphonates in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 21 (S1), 30. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (May 2010). The burden of non-adherence with oral bisphosphonates and the potential cost-effectiveness of adherence-enhancing interventions. Osteoporosis International, 21 (S1), 381. Peer Reviewed verified by ORBi |
 | Neuprez, A., Johansson, H., Kanis, J., McCloskey, E. V., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J., Kaufman, J., & Reginster, J.-Y. (May 2010). A FRAX® model for the assessment of fracture probability in Belgium. Osteoporosis International, 21 (Suppl.1), 255. Peer Reviewed verified by ORBi |
 | Hiligsmann, M. (2010). Evaluation économique de la prise en charge de l'ostéoporose [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/40956 |
 | Reginster, J.-Y., Neuprez, A., Hiligsmann, M., & Bruyère, O. (February 2010). Oral calcitonin in the management of osteoarthritis: hope or fantasy ? International Journal of Clinical Rheumatology, 5 (1), 53-58. doi:10.2217/ijr.09.68 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Gathon, H.-J., Bruyère, O., Ethgen, O., Rabenda, V., & Reginster, J.-Y. (2010). Cost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence. Value in Health, 13 (4), 394-401. doi:10.1111/j.1524-4733.2009.00687.x Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2010). Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. BONE, 46 (2), 440-6. doi:10.1016/j.bone.2009.08.052 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (2010). The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy, 96, 170-176. doi:10.1016/j.healthpol.2010.01.014 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (2010). Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. Calcified Tissue International, 86, 202-210. doi:10.1007/s00223-009-9329-4 Peer Reviewed verified by ORBi |
 | SCHOLTISSEN, S., Bruyère, O., NEUPREZ, A., Severens, J. L., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (2010). Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. International Journal of Clinical Practice, 64 (6), 756-62. doi:10.1111/j.1742-1241.2010.02362.x Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2010). Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporosis International, 21, 157-165. doi:10.1007/s00198-009-0924-z Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2010). Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. BONE, 47, 34-40. doi:10.1016/j.bone.2010.03.009 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Vanoverberghe, M., Neuprez, A., Bruyère, O., & Reginster, J.-Y. (2010). Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 10 (4), 359-366. doi:10.1586/erp.10.53 Peer Reviewed verified by ORBi |
 | Neuprez, A., Johansson, H., Kanis, J., McCloskey, E. V., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J.-P., Kaufmann, J.-M., & Reginster, J.-Y. (December 2009). Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l’intégration des facteurs cliniques de risque fracturaire. Validation de l’algorithme FRAX®. Revue Médicale de Liège, 64 (12), 612-619. Peer reviewed |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (October 2009). The clinical and economic burden of nonadherence with osteoporosis medications. Value in Health, 12 (7), 444. doi:10.1016/S1098-3015(10)75197-4 Peer Reviewed verified by ORBi |
 | Bruyère, O., COLLETTE, J., DEROISY, R., Rabenda, V., Neuprez, A., Hiligsmann, M., & Reginster, J.-Y. (October 2009). Biochemical markers of bone and cartilage remodelling: interest in the prediction of lumbar disc degeneration progression and effects of strontium ranelate over a 3-year period. Arthritis and Rheumatism, 60 (number 10 (suppl.)), 313. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (October 2009). The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Arthritis and Rheumatism, 60 (number 10 (suppl.)), 328. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., & Reginster, J.-Y. (June 2009). The clinical and economic burden of nonadherence with oral bisphosphonates in osteoporotic patients. Annals of the Rheumatic Diseases, 68 (S3), 667. Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., Deroisy, R., Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (March 2009). Prediction of spinal osteoarthritis progression by assessment of biochemical markers of bone and cartilage remodelling: a 3-year study. Osteoporosis International, 20 (Suppl.1), 8. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (March 2009). Cost-utility of denosumab for the treatment of postmenopausal osteoporotic women. Osteoporosis International, 20 (S1), 5. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Neuprez, A., Scholtissen, S., & Reginster, J.-Y. (March 2009). Cost-effectiveness of strontium ranelate versus intravenous ibandronate in the treatment of postmenopausal women. Osteoporosis International, 20 (S1), 130. Peer Reviewed verified by ORBi |
 | Bruyère, O., Hiligsmann, M., Frankinet, P., Detilleux, J., & Reginster, J.-Y. (March 2009). Association between changes in bone mineral density and fracture incidence in postmenopausal women receiving calcium and vitamin D : A 3-year study. Osteoporosis International, 20 (Suppl.1), 87-88. Peer Reviewed verified by ORBi |
 | Scholtissen, S., Bruyère, O., Hiligsmann, M., Neuprez, A., Pavelka, K., Rovati, L., & Reginster, J.-Y. (March 2009). Effect of glucosamine sulfate on health utility data in patients with knee osteoarthritis : reanalysis of two 3-year prospective studies. Osteoporosis International, 20 (Suppl.1), 18. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (March 2009). Clinical en economic implications of non-adherence with osteoporosis medications. Osteoporosis International, 20 (S1), 16. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (March 2009). Cost-utility of strontium ranelate for the prevention and treatment of postmenopausal osteoporotic women. Osteoporosis International, 20 (S1), 129. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Devogelaer, J.-P., Hiligsmann, M., Kaufman, J.-M., Neuprez, A., Johansson, H., & Kanis, J. A. (March 2009). FRAX(r) and the assessment of fracture probability in men and women from Belgium. Osteoporosis International, 20 (Suppl.1), 38-39. Peer Reviewed verified by ORBi |
 | Scholtissen, S., Bruyère, O., Hiligsmann, M., Neuprez, A., Herrero-Beaumont, G., Rovati, L., & Reginster, J.-Y. (March 2009). Glucosamine sulfate in the treatment of knee osteoarthritis: impact on health utility. Osteoporosis International, 20 (Suppl.1), 149. Peer Reviewed verified by ORBi |
 | Bruyère, O., Scholtissen, S., Neuprez, A., Severens, H., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (2009). Analyses coût-efficacité du sulfate de glucosamine chez des patients gonarthrosiques : comparaison avec le paracétamol. Revue du Rhumatisme, 76, 1097. Peer Reviewed verified by ORBi |
 | Bruyère, O., Scholtissen, S., Neuprez, A., Hiligsmann, M., & Reginster, J.-Y. (2009). Effets du sulfate de chondroitine sur les indices d'utilité de santé chez des sujets gonarthrosiques et analyses économiques préliminaires. Revue du Rhumatisme, 76, 1051. Peer Reviewed verified by ORBi |
 | Bruyère, O., Varela, A. R., Adami, S., Detilleux, J., Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (2009). Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women. European Journal of Epidemiology, 24, 707-712. doi:10.1007/s10654-009-9381-4 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ethgen, O., Bruyère, O., Richy, F., Gathon, H.-J., & Reginster, J.-Y. (2009). Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis. Value in Health, 12 (5), 687-696. doi:10.1111/j.1524-4733.2008.00497.x Peer Reviewed verified by ORBi |
 | NEUPREZ, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2009). Efficacite anti-fracturaire de l'ibandronate administre par voie intraveineuse: de la complexite des etudes epidemiologiques interventionnelles a la pratique quotidienne. Revue Médicale de Liège, 64 (10), 525-9. Peer reviewed |
 | Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (2009). Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opinion on Pharmacotherapy, 10 (14), 2303-15. doi:10.1517/14656560903140533 Peer Reviewed verified by ORBi |
 | Neuprez, A., Johansson, H., Kanis, J., Mc Closkey, E., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J.-P., Kaufman, J.-M., & Reginster, J.-Y. (2009). Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l'intégration des facteurs cliniques de risque fracturaire. Validation de l'algorithme FRAX(r). Revue du Rhumatisme, 76, 1070-1. Peer Reviewed verified by ORBi |
 | Bruyère, O., SCHOLTISSEN, S., NEUPREZ, A., Hiligsmann, M., Toukouki, A., & Reginster, J.-Y. (2009). Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. Journal of Medical Economics, 12 (4), 356-360. doi:10.3111/13696990903438617 Peer Reviewed verified by ORBi |
Ethgen, O., Hiligsmann, M., & Reginster, J.-Y. (2009). Modelling the uptake and diffusion of innovative technology: a critical and strategic feature of budget impact analysis and risk-sharing agreements. In Value in Health (pp. 12, A395). Peer reviewed |
 | Reginster, J.-Y., Hiligsmann, M., Rabenda, V., Zegels, B., Neuprez, A., & Bruyère, O. (2009). Ibandronate in the management of postmenopausal osteoporosis. Clinical Medicine. Therapeutics, 1, 1409-1421. Peer reviewed |
 | Reginster, J.-Y., Deroisy, R., NEUPREZ, A., Hiligsmann, M., Zegels, B., & Bruyère, O. (2009). Strontium ranelate: new data on fracture prevention and mechanisms of action. Current Osteoporosis Reports, 7 (3), 96-102. doi:10.1007/s11914-009-0016-1 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (December 2008). Cost-utility of calcium and vitamin D supplementation in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 19 (S2), 363. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (December 2008). Impact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis. Osteoporosis International, 19 (S2), 282. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (December 2008). Cost-utility of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 19 (S2), 450. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (November 2008). Impact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis. Value in Health, 11 (6), 542. doi:10.1016/S1098-3015(10)66788-5 Peer Reviewed verified by ORBi |
 | Bruyère, O., Hiligsmann, M., FRANKINET, P., Detilleux, J., & Reginster, J.-Y. (October 2008). Association between changes in bone mineral density and fracture incidence in postmenopausal osteoporotic women receiving calcium and vitamin D: a 3-year follow-up study. Arthritis and Rheumatism, 58 (Suppl.1), 743. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (July 2008). Efficiency of calcium and vitamin D in the management of osteoporosis [Paper presentation]. 7th European Conference on Health Economics, Rome, Italy. |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., Pire, G., Gathon, H.-J., & Reginster, J.-Y. (July 2008). Efficiency and recommendations for osteoporosis screening strategy [Paper presentation]. 7th European Conference on Health Economics, Rome, Italy. |
 | Bruyère, O., Brandi, M., Vellas, B., Hiligsmann, M., & Reginster, J.-Y. (June 2008). Relationship between long-term changes in femoral neck bone mineral density and hip fracture incidence in untreated postmenopausal osteoporotic women. Annals of the Rheumatic Diseases, 67 (Suppl.II), 403. Peer Reviewed verified by ORBi |
 | Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (June 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 428. Peer Reviewed verified by ORBi |
| Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (April 2008). Efficiency of calcium and vitamin D supplementation in the management of osteoporosis. Osteoporosis International, 19 (S1), 113. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., Pire, G., & Reginster, J.-Y. (April 2008). Efficiency and recommendations for osteoporosis screening strategy. Osteoporosis International, 19 (S1), 116. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (April 2008). Cost-utility of strontium ranelate in the treatment of postmenopausal women. Osteoporosis International, 19 (S1), 6. Peer Reviewed verified by ORBi |
 | Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (April 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Osteoporosis International, 19 (Suppl.1), 200. Peer Reviewed verified by ORBi |
 | Bruyère, O., Brandi, M. L., Vellas, B., Hiligsmann, M., & Reginster, J.-Y. (April 2008). Changes in femoral neck bone mineral density are associated with hip fracture incidence in untreated postmenopausal women. Osteoporosis International, 19 (Suppl.1), 18-19. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (April 2008). Cost-effectiveness of mass screening and targeted biphosphonates treatment in osteoporosis. Osteoporosis International, 19 (S1), 117. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2008). Risque à long terme de survenue d'une fracture ostéoporotique en Belgique. Revue Médicale de Liège, 63 (7-8), 480-487. Peer reviewed |
 | Hiligsmann, M., Bruyère, O., Pire, G., & Reginster, J.-Y. (2008). Evaluation économique de la campagne de dépistage de l'ostéoporose menée en Province de Liège avec le concours de Liège Province Santé. Revue Médicale de Liège, 63 (10), 588-94. Peer reviewed |
 | Bruyère, O., Hiligsmann, M., FRANKINET, P., Detilleux, J., & Reginster, J.-Y. (2008). Association between changes in bone mineral density and fracture incidence in postmenopausal osteoporotic women receiving calcium and vitamin D : a 3-year follow-up study. Osteoporosis International, 19 (S2), 274. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (2008). An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis. Disease Management and Health Outcomes, 16 (6), 429-438. doi:10.2165/0115677-200816060-00008 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., Gathon, H.-J., & Reginster, J.-Y. (2008). Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. BONE, 43 (6), 991-4. doi:10.1016/j.bone.2008.08.119 Peer Reviewed verified by ORBi |
 | NEUPREZ, A., Hiligsmann, M., Scholtissen, S., Bruyère, O., & Reginster, J.-Y. (2008). Strontium ranelate: The first agent of a new therapeutic class in osteoporosis. Advances in Therapy, 25 (12), 1235-56. doi:10.1007/s12325-008-0125-8 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ethgen, O., Richy, F., & Reginster, J.-Y. (2008). Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcified Tissue International, 82 (4), 288-92. doi:10.1007/s00223-008-9117-6 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (December 2007). Efficience d'un dépistage de masse de l'ostéoporose par ultrasons: approche économique par microsimulation. Revue du Rhumatisme, 74 (10-11), 1072-3. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (December 2007). Analyse coût-efficacité d'un dépistage de masse de l'ostéoporose par DEXA combiné à un traitement par alendronate chez la femme ostéoporotique. Revue du Rhumatisme, 74 (10-11), 1072-3. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (October 2007). Cost-effectiveness of bone densitometry screening combined with alendronate therapy for those who have osteoporosis. Value in Health, 10 (6), 236. doi:10.1016/S1098-3015(10)64899-1 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (October 2007). Cost-effectiveness of osteoporosis screening campaign for Belgian women. Value in Health, 10 (6), 395. doi:10.1016/S1098-3015(10)65384-3 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Richy, F., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (March 2007). Rationale and development of an individual patient-based model to accurately assess the efficacy of osteoporosis management. Osteoporosis International, 18 (S1), 169. Peer Reviewed verified by ORBi |
 | Neuprez, A., Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (2007). Prevention of hip fractures in osteoporosis. Minerva Ortopedica e Traumatologica, 58 (5), 423-437. Peer reviewed |
 | Richy, F. Y., Hiligsmann, M., & Reginster, J.-Y. (November 2006). Prescription and coprescription patterns of bone-active substances among postmenopausal women: an epidemiological study in Belgium, Europe. Arthritis and Rheumatism, 54, 84. Peer Reviewed verified by ORBi |